2.04
price down icon1.92%   -0.04
after-market After Hours: 2.03 -0.01 -0.49%
loading
Ventyx Biosciences Inc stock is traded at $2.04, with a volume of 902.90K. It is down -1.92% in the last 24 hours and down -17.07% over the past month. Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$2.08
Open:
$2.04
24h Volume:
902.90K
Relative Volume:
0.63
Market Cap:
$188.58M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.6182
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
-4.67%
1M Performance:
-17.07%
6M Performance:
-19.05%
1Y Performance:
-6.42%
1-Day Range:
Value
$2.00
$2.11
1-Week Range:
Value
$1.95
$2.195
52-Week Range:
Value
$0.783
$3.39

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Name
Ventyx Biosciences Inc
Name
Phone
(858) 945-2393
Name
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Employee
79
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
VTYX's Discussions on Twitter

Compare VTYX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VTYX
Ventyx Biosciences Inc
2.04 188.58M 0 -192.96M -167.04M -3.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.41 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.11 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
546.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.99 28.51B 3.81B -644.79M -669.77M -6.24

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-24 Upgrade Oppenheimer Perform → Outperform
Mar-12-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-07-23 Downgrade H.C. Wainwright Buy → Neutral
Nov-07-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-07-23 Downgrade Oppenheimer Outperform → Perform
Nov-07-23 Downgrade Stifel Buy → Hold
Nov-07-23 Downgrade Wells Fargo Overweight → Equal Weight
Jun-14-23 Resumed Credit Suisse Outperform
Mar-21-23 Initiated Wells Fargo Overweight
Dec-19-22 Initiated Goldman Buy
Nov-17-22 Initiated Morgan Stanley Overweight
Sep-07-22 Initiated Stifel Buy
Sep-01-22 Initiated H.C. Wainwright Buy
May-09-22 Initiated Credit Suisse Outperform
Mar-31-22 Initiated Canaccord Genuity Buy
Feb-01-22 Initiated Oppenheimer Outperform
Nov-15-21 Initiated Jefferies Buy
Nov-15-21 Initiated Piper Sandler Overweight
View All

Ventyx Biosciences Inc Stock (VTYX) Latest News

pulisher
Jun 18, 2025

Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 15, 2025

Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria

Jun 15, 2025
pulisher
Jun 12, 2025

Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Ventyx Biosciences reports annual meeting results - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

Piper Sandler maintains $21 target on Ventyx stock - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

As Ventyx Approaches Multiple Phase II Readouts, What Could Be Next For The Stock? - RTTNews

Jun 09, 2025
pulisher
Jun 09, 2025

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Two Sigma Investments LP Has $1.04 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ventyx Biosciences at Jefferies Conference: Strategic Developments in Focus By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 01, 2025

Millennium Management LLC Purchases 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025
pulisher
May 29, 2025

Northern Trust Corp Buys 19,982 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 29, 2025
pulisher
May 28, 2025

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Ventyx Biosciences Executives Set for Key Presentation on Autoimmune Drug Pipeline at Jefferies Conference - Stock Titan

May 28, 2025
pulisher
May 28, 2025

BNP Paribas Financial Markets Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 28, 2025
pulisher
May 25, 2025

Bank of America Corp DE Has $9.36 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 25, 2025
pulisher
May 22, 2025

Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews

May 22, 2025
pulisher
May 21, 2025

Spotlight On 3 Penny Stocks With Market Caps Under $500M - simplywall.st

May 21, 2025
pulisher
May 21, 2025

VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

May 21, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Sells 13,616 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 19, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Makes New $347,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 17, 2025
pulisher
May 13, 2025

Barclays PLC Boosts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 13, 2025
pulisher
May 11, 2025

VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

May 11, 2025
pulisher
May 10, 2025

Mariner LLC Sells 8,485 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 10, 2025
pulisher
May 09, 2025

Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Ventyx Biosciences Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Investors who lost money on Ventyx Biosciences, Inc. (VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Lost Money on Ventyx Biosciences, Inc.(VTYX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Shareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Market Resilience: Ventyx Biosciences Inc (VTYX) Finishes Weak at 1.28, Down -5.88 - DWinneX

May 08, 2025
pulisher
May 08, 2025

Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc. - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Ratios Uncovered: Breaking Down Ventyx Biosciences Inc (VTYX)’s Trailing Twelve Months Metrics - DWinneX

May 07, 2025
pulisher
May 05, 2025

Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

May 05, 2025

Ventyx Biosciences Inc Stock (VTYX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Ventyx Biosciences Inc Stock (VTYX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mohan Raju
CEO AND PRESIDENT
Mar 28 '25
Option Exercise
0.00
11,844
0
2,303,540
Nuss John
CHIEF SCIENTIFIC OFFICER
Mar 28 '25
Option Exercise
0.00
4,531
0
469,113
Nuss John
CHIEF SCIENTIFIC OFFICER
Dec 27 '24
Sale
2.36
21,119
49,841
464,582
$20.52
price up icon 1.08%
$35.59
price down icon 2.14%
$22.61
price down icon 7.90%
$96.95
price down icon 0.87%
$110.05
price up icon 0.05%
biotechnology ONC
$240.99
price down icon 1.83%
Cap:     |  Volume (24h):